AbCellera Biologics EBIT

AbCellera Biologics (ABCL) currently reports a EBIT of $-200M as of June 2026. That compares with $-220M in the prior-year period — up 8.0% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore AbCellera Biologics's EBIT history and peer comparisons.

AbCellera Biologics's EBIT increased from $-220M to $-200M — a 8.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AbCellera Biologics's EBIT of $-200M is lower than the its sector sector average of $-6.4M. That is roughly 3098.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AbCellera Biologics reported $-200M in EBIT as of June 2026. That compares with $-220M in the prior-year period — up 8.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-200M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for AbCellera Biologics, and consider following ABCL for alerts when major investors trade the stock.